Allarity Therapeutics Inc
ALLRBuild a strategy around ALLR
Allarity Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue TTM with 16.9M cash and -15.1M annual burn rate implies ~13 months runway without additional financing.[Cash and Equivalents]
- R&D of 6.8M TTM is 40% of operating expenses - below industry median of 45M, limiting pipeline advancement capacity.[Research and Development TTM]
- EV of 1.3M vs market cap 16.8M - net cash position makes enterprise nearly free if pipeline has any value.[Enterprise Value]
Watch Triggers
- Cash and Equivalents: Falls below 10M — Triggers distressed financing at unfavorable terms, severe dilution risk
- Issuance of Capital Stock: Exceeds 5M in any quarter — Signals accelerated dilution and potential cash crisis
- Research and Development TTM: Declines below 5M — Indicates pipeline deprioritization or capital preservation mode
Bull Case
Trading at 1.4x book with 1.3M EV - market assigns near-zero value to pipeline. Any clinical success creates asymmetric upside.
Minimal debt (1.4M, 0.12 D/E) and 11.7M working capital provide flexibility for partnerships without distressed negotiations.
Bear Case
Zero revenue biotech with -15.3M net loss TTM and declining cash (16.9M from 17.8M) - dilutive financing inevitable within 12 months.
R&D spend of 6.8M is 85% below industry median - insufficient scale to advance meaningful clinical programs competitively.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage ALLR's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary outcome: either secures partnership/financing within 12 months or faces severe dilution/failure.
- Cash runway exhausts by late 2026 at current burn
- No revenue path without clinical milestone success
- Recent 2.5M equity issuance signals ongoing capital needs
Valuation Context
Caveats
Public Strategies Rankings
See how Allarity Therapeutics Inc ranks across different investment strategies.
Leverage ALLR's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
ALLR Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$18.61M | — | ||
$5.33M | — | ||
0.00 | — | ||
$320,000 | — | ||
$-0.78 | — | ||
-3,939% | -3939.1% | — | |
-3,510% | -3509.7% | — | |
$-14.83M | — | ||
-104% | — | ||
Beta 5Y (Monthly) | unknown | — |
ALLR Dividend History
ALLR Stock Splits
ALLR SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/30/26 | 12/31/25 | Unknown | |
11/14/25 | 09/30/25 | 10-Q | |
08/15/25 | 06/30/25 | 10-Q | |
05/09/25 | 03/31/25 | 10-Q | |
03/31/25 | 12/31/24 | Unknown | |
11/14/24 | 09/30/24 | 10-Q | |
08/05/24 | 06/30/24 | 10-Q | |
05/14/24 | 03/31/24 | 10-Q | |
03/08/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/14/23 | 06/30/23 | 10-Q | |
05/11/23 | 03/31/23 | 10-Q | |
03/13/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
10/07/22 | 06/30/22 | 10-Q | |
05/27/22 | 03/31/22 | 10-Q | |
05/17/22 | 12/31/21 | 10-K | |
12/21/21 | 09/30/21 | 424B3 | |
10/07/22 | 06/30/21 | 10-Q | |
05/27/22 | 03/31/21 | 10-Q | |
12/21/21 | 12/21/20 | 424B3 | |
05/17/22 | 09/30/20 | 10-Q/A |